ABOUT US

A WORD FROM OUR FOUNDERS

Proven by research. Designed for life.
Dr. Clemens Fischer
Founder & CEO FUTRUE
Madlena Hohlefelder
Founder & CSO FUTRUE

While groundbreaking advances are being made in areas such as artificial intelligence and space travel, the healthcare sector remains largely stagnant despite isolated successes. The development of new medications now takes twice as long as it did 20 years ago. Instead of investing comprehensively in prevention, over 95% of healthcare spending goes into treating chronic diseases. Chronic pain continues to be treated with opioids, which have numerous side effects, due to a lack of alternatives. Even for everyday ailments such as the common cold or flu, there is still no treatment available.

The time for fundamental changes to our healthcare system is now!

That's why we founded FUTRUE, a healthcare group with more than 20 pharmaceutical companies worldwide.

Dr. Clemens Fischer
Founder & CEO FUTRUE
Madlena Hohlefelder
Founder & CSO FUTRUE

OUR VISION

Make probiotics the foundation of a longer, healthier life – for all

As Europe's leading probiotics brand, Kijimea has set itself a major goal: to make probiotics the basis for a longer, healthier life - for everyone.

Why are we firmly convinced that we are on the right track with our commitment? We believe in the power and potential of the microscopic helpers that we pay far too little attention to in everyday life - the intestinal bacteria.

We were inspired by a major scientific breakthrough: in 2001, Nobel Prize winner Professor Joshua Lederberg coined the term ‘microbiome’. It was only after this milestone that research into the ecosystem known at the time as ‘gut flora’, which was still in its infancy, gained momentum.

Large-scale projects such as the ‘Human Microbiome Project’ or the ‘American Gut Project’ have put the microbiome where it belongs in recent years: at the centre of attention in scientific circles! Its importance can no longer be denied.

Kijimea recognised the potential of the microbiome for health early on and pioneered its application in humans. Since then, the scientific approach has become the basis of our philosophy: ‘Proven by research. Designed for life’. We are committed to the highest quality research - double-blind, placebo-controlled and randomised - to look after your health.

We collaborate with leading microbiome researchers and scientific institutions around the world, including the Charité in Berlin, maintaining long-term, close relationships.

Our ambition since our founding in 2011 has driven us to fight the stigma surrounding a common and highly debilitating disease - irritable bowel syndrome.

OUR ORIGINS

From the discovery of the unique B. bifidum HI-MIMBb75 to the world's leading probiotics provider

With the discovery of the unique, patented bacterial strain B. bifidum MIMBb75, which symbolically attaches itself to the damaged intestinal barrier like a plaster, we achieved a decisive breakthrough: our strictly scientific approach also convinced renowned experts and doctors, as a result of which B. bifidum MIMBb75 is even recommended in the S3 guideline for the treatment of irritable bowel syndrome.

In its further developed heat-inactivated form, which is only contained in Kijimea IBS PRO, B. bifidum HI-MIMBb75 is regarded as a revolutionary therapy for irritable bowel syndrome, which has helped millions of people worldwide to live a better life.

Our product range has grown over the years in line with the increasing amount of knowledge about the microbiome. In over ten European countries, our portfolio addresses important topics such as women's health, healthy skin and the important gut-brain axis.

We are particularly proud of our broad-spectrum multibiotic Kijimea K53 Advance, which is unique on the market in its diversity and variety of bacteria and imitates the natural gut microbiome in an unrivalled way.

10
In 10 European countries and others are in the process of being established
10million
Satisfied customers
100
Evidence-based